The only milestones that matter are the US FDA and trial results. The rest are just noise, a distraction for the company and a way to burn cash needed to invest in a more focused strategy and making sure that you have the US prefessional societies on your side and max out the reimbursement fees. Both Sirtex and Therasphere hold value becasue of their US business the ROW stuff rides on the back of that and TBH could be zero and would probably make them more profitable. China is a pipe dream.
Ann: First Patient in Australia Randomised in TRIPP-FFX Trial, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 123 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 46 | 2 |
View Market Depth
| Last trade - 09.05am 18/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |
Day chart unavailable